Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

McGill University

$105,000.00

COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial

FY 2022-23

Summary
The ongoing COVID pandemic, caused by SARS-CoV-2, has resulted in more than 531 million infections and 6.3 million deaths. With the emergence of new variants escaping vaccine-induced immunity, COVID is unlikely to be eradicated. Furthermore, long COVID symptoms affect up to 50% of hospitalized patients and represent another public health threat. Despite unprecedented global research efforts, therapeutic knowledge gaps remain in severe illness and in long- COVID. Current treatments are limited by their side effect profiles and efficacy in new variants such as Omicron. Alternative treatments with dual antiviral and anti-inflammatory properties are required. Omalizumab is an anti-IgE monoclonal antibody approved by Health Canada to treat chronic idiopathic urticaria and asthma. The safety of omalizumab has been extensively demonstrated, particularly in patients with multiple comorbidities such as those seen in hospitalized COVID patients. Omalizumab's antiviral effect has been suggested to stem from enhancing antiviral cytokines. In addition, omalizumab suppresses degranulation of inflammatory cells thought to contribute to the inflammatory response and lung remodelling in severe COVID. Taken together, omalizumab's antiviral and anti- inflammatory properties support the need for a randomized controlled trial comparing omalizumab to placebo in the treatment of COVID. The CIAO trial is a randomized, placebo-controlled trial currently conducted at McGill University, Sunnybrook and Niagara Health Centres that examines the efficacy and safety of a single dose of omalizumab in hospitalized adult COVID patients. The viability of this trial is reflected by consistent recruitment rates and adherence to treatment protocols. By identifying a potentially efficacious treatment for hospitalized COVID patients, this study aims to improve patient survival and reduce the burden of this globally devastating disease on the healthcare system.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
475843
Name
Le Michelle
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Clinical Trial; Covid-19; Long-Covid; Therapeutics
Abstract
The ongoing COVID pandemic, caused by SARS-CoV-2, has resulted in more than 531 million infections and 6.3 million deaths. With the emergence of new variants escaping vaccine-induced immunity, COVID is unlikely to be eradicated. Furthermore, long COVID symptoms affect up to 50% of hospitalized patients and represent another public health threat. Despite unprecedented global research efforts, therapeutic knowledge gaps remain in severe illness and in long- COVID. Current treatments are limited by their side effect profiles and efficacy in new variants such as Omicron. Alternative treatments with dual antiviral and anti-inflammatory properties are required. Omalizumab is an anti-IgE monoclonal antibody approved by Health Canada to treat chronic idiopathic urticaria and asthma. The safety of omalizumab has been extensively demonstrated, particularly in patients with multiple comorbidities such as those seen in hospitalized COVID patients. Omalizumab's antiviral effect has been suggested to stem from enhancing antiviral cytokines. In addition, omalizumab suppresses degranulation of inflammatory cells thought to contribute to the inflammatory response and lung remodelling in severe COVID. Taken together, omalizumab's antiviral and anti- inflammatory properties support the need for a randomized controlled trial comparing omalizumab to placebo in the treatment of COVID. The CIAO trial is a randomized, placebo-controlled trial currently conducted at McGill University, Sunnybrook and Niagara Health Centres that examines the efficacy and safety of a single dose of omalizumab in hospitalized adult COVID patients. The viability of this trial is reflected by consistent recruitment rates and adherence to treatment protocols. By identifying a potentially efficacious treatment for hospitalized COVID patients, this study aims to improve patient survival and reduce the burden of this globally devastating disease on the healthcare system.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Le, Michelle
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2022-23) | Canada Spends